FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201311188> ?p ?o ?g. }

• W3201311188 endingPage "882" @default.
• W3201311188 startingPage "871" @default.
• W3201311188 abstract "Few studies have described real-world treatment patterns and survival before the widespread use of immune checkpoint inhibitors (ICIs). We aimed to describe anti-cancer treatment including the use of programmed cell death-1 and ligand-1 (PD-1/PD-L1) ICIs and overall survival (OS) in advanced cancer patients as a benchmarking real-world standard before widespread use of ICIs.Using nationwide Danish medical registries, we assembled cohorts of Danish patients with advanced non-small cell lung cancer (NSCLC) (n=12,283), urothelial carcinoma (n=2504), epithelial ovarian cancer (n=1466), gastric adenocarcinoma (n=1457), and renal cell carcinoma (RCC) (n=1261) diagnosed between 1/1/2013 and 31/12/2017. We describe anti-cancer treatment and OS using proportions, medians, and Kaplan-Meier methods.Between 9% (ovarian cancer) and 25% (gastric adenocarcinoma) of patients did not receive anti-cancer treatment. The remaining patients received surgery, radiation therapy, and/or medical therapy. Chemotherapy was the most frequent medical therapy in all cohorts except for RCC (tyrosine kinase inhibitors). PD-L1/PD-1 ICIs were used in 7-8% of the NSCLC and RCC cohorts-mainly as second or higher line treatments. OS was longest in patients starting treatment with surgery (eg 25.6 months [95%-confidence interval (CI)=21.9-29.4] for NSCLC and 21.4 months [95%-CI=19.8-23.5] for urothelial carcinoma) and shortest for radiation therapy (eg 3.9 months [95%-CI=3.6-4.2] for NSCLC and 12.6 months [95%-CI=9.2-17.5] for urothelial carcinoma). NSCLC patients starting with medical therapy had OS between these limits. Median OS for NSCLC patients starting treatment with PD-L1/PD-1 ICIs was 21.4 months (95%-CI=13.9-not estimable).Most patients with advanced NSCLC, urothelial carcinoma, epithelial ovarian cancer, gastric adenocarcinoma and RCC had poor OS in an era where only a minority received PD-L1/PD-1 ICIs. This information on treatment patterns and survival is important as a benchmarking real-world standard before widespread use of ICIs." @default.
• W3201311188 created "2021-09-27" @default.
• W3201311188 creator A5026020623 @default.
• W3201311188 creator A5037182167 @default.
• W3201311188 creator A5037503101 @default.
• W3201311188 creator A5042375186 @default.
• W3201311188 creator A5054122582 @default.
• W3201311188 creator A5055440728 @default.
• W3201311188 creator A5058966531 @default.
• W3201311188 creator A5059200225 @default.
• W3201311188 creator A5060416587 @default.
• W3201311188 creator A5066076502 @default.
• W3201311188 creator A5076870585 @default.
• W3201311188 creator A5079598384 @default.
• W3201311188 date "2021-09-01" @default.
• W3201311188 modified "2023-10-17" @default.
• W3201311188 title "Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation" @default.
• W3201311188 cites W1978670003 @default.
• W3201311188 cites W2000445173 @default.
• W3201311188 cites W2004414518 @default.
• W3201311188 cites W2029008405 @default.
• W3201311188 cites W2052654273 @default.
• W3201311188 cites W2097206214 @default.
• W3201311188 cites W2141444851 @default.
• W3201311188 cites W2144330816 @default.
• W3201311188 cites W2160208506 @default.
• W3201311188 cites W2168905545 @default.
• W3201311188 cites W2180984345 @default.
• W3201311188 cites W2219591537 @default.
• W3201311188 cites W2594332338 @default.
• W3201311188 cites W2783137027 @default.
• W3201311188 cites W2784210180 @default.
• W3201311188 cites W2886357811 @default.
• W3201311188 cites W2886987811 @default.
• W3201311188 cites W2896622101 @default.
• W3201311188 cites W2896672682 @default.
• W3201311188 cites W2902968854 @default.
• W3201311188 cites W2913505192 @default.
• W3201311188 cites W2925030036 @default.
• W3201311188 cites W2948873563 @default.
• W3201311188 cites W2955678947 @default.
• W3201311188 cites W2958564402 @default.
• W3201311188 cites W2970142977 @default.
• W3201311188 cites W2973095792 @default.
• W3201311188 cites W2973110226 @default.
• W3201311188 cites W3029371683 @default.
• W3201311188 cites W3029693423 @default.
• W3201311188 cites W3112964456 @default.
• W3201311188 cites W4238604577 @default.
• W3201311188 cites W4255387133 @default.
• W3201311188 cites W4293241248 @default.
• W3201311188 doi "https://doi.org/10.2147/clep.s326470" @default.
• W3201311188 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8473934" @default.
• W3201311188 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34588817" @default.
• W3201311188 hasPublicationYear "2021" @default.
• W3201311188 type Work @default.
• W3201311188 sameAs 3201311188 @default.
• W3201311188 citedByCount "1" @default.
• W3201311188 countsByYear W32013111882022 @default.
• W3201311188 crossrefType "journal-article" @default.
• W3201311188 hasAuthorship W3201311188A5026020623 @default.
• W3201311188 hasAuthorship W3201311188A5037182167 @default.
• W3201311188 hasAuthorship W3201311188A5037503101 @default.
• W3201311188 hasAuthorship W3201311188A5042375186 @default.
• W3201311188 hasAuthorship W3201311188A5054122582 @default.
• W3201311188 hasAuthorship W3201311188A5055440728 @default.
• W3201311188 hasAuthorship W3201311188A5058966531 @default.
• W3201311188 hasAuthorship W3201311188A5059200225 @default.
• W3201311188 hasAuthorship W3201311188A5060416587 @default.
• W3201311188 hasAuthorship W3201311188A5066076502 @default.
• W3201311188 hasAuthorship W3201311188A5076870585 @default.
• W3201311188 hasAuthorship W3201311188A5079598384 @default.
• W3201311188 hasBestOaLocation W32013111881 @default.
• W3201311188 hasConcept C121608353 @default.
• W3201311188 hasConcept C126322002 @default.
• W3201311188 hasConcept C143998085 @default.
• W3201311188 hasConcept C207103383 @default.
• W3201311188 hasConcept C2776256026 @default.
• W3201311188 hasConcept C2777472916 @default.
• W3201311188 hasConcept C2781068499 @default.
• W3201311188 hasConcept C2781182431 @default.
• W3201311188 hasConcept C44249647 @default.
• W3201311188 hasConcept C71924100 @default.
• W3201311188 hasConceptScore W3201311188C121608353 @default.
• W3201311188 hasConceptScore W3201311188C126322002 @default.
• W3201311188 hasConceptScore W3201311188C143998085 @default.
• W3201311188 hasConceptScore W3201311188C207103383 @default.
• W3201311188 hasConceptScore W3201311188C2776256026 @default.
• W3201311188 hasConceptScore W3201311188C2777472916 @default.
• W3201311188 hasConceptScore W3201311188C2781068499 @default.
• W3201311188 hasConceptScore W3201311188C2781182431 @default.
• W3201311188 hasConceptScore W3201311188C44249647 @default.
• W3201311188 hasConceptScore W3201311188C71924100 @default.
• W3201311188 hasLocation W32013111881 @default.
• W3201311188 hasLocation W32013111882 @default.
• W3201311188 hasLocation W32013111883 @default.
• W3201311188 hasLocation W32013111884 @default.
• W3201311188 hasOpenAccess W3201311188 @default.

• next